预约演示

更新于：2025-01-23

MT104

更新于：2025-01-23

概要

概要

基本信息

药物类型

寡核苷酸

别名-

靶点-

作用机制-

治疗领域

神经系统疾病其他疾病

在研适应症

阿尔茨海默症认知功能障碍

非在研适应症-

原研机构

Mthera Pharma初创企业

在研机构

Mthera Pharma初创企业

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构/序列

使用我们的RNA技术数据为新药研发加速。

或

查看完整样例数据

关联

项与 MT104 相关的临床试验

KCT0006499

/ CompletedN/AIIT

Single center, randomized, double-blind, placebo-controlled clinical trial for evaluation of efficacy on cognitive function and safety of MT104

开始日期2021-07-01

申办/合作机构-

100 项与 MT104 相关的临床结果

登录后查看更多信息

100 项与 MT104 相关的转化医学

登录后查看更多信息

100 项与 MT104 相关的专利（医药）

登录后查看更多信息

项与 MT104 相关的文献（医药）

2019-08-27·Blood Advances2区 · 医学

Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab

2区 · 医学

Article

作者: Sayehli, Cyrus M. ; Chatterjee, Manik ; Dufner, Vera ; Gelbrich, Götz ; Bargou, Ralf C. ; Goebeler, Maria-Elisabeth ; Hummel, Horst D.

AbstractBlinatumomab, the first-in-class CD3/CD19 bispecific T-cell engager antibody construct, has recently been approved for treating patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia. However, the clinical proof of concept of blinatumomab efficacy was initially demonstrated in patients with R/R B-cell non-Hodgkin lymphoma (B-NHL) in the MT103-104 phase 1 dose-escalation and expansion trial (NCT00274742), which defined 60 µg/m2 per day as the maximum tolerated dose (MTD). The clinically most relevant adverse effects were neurologic symptoms and cytokine release syndrome. Currently, there are no data on long-term outcomes and toxicity for B-NHL patients receiving blinatumomab treatment, so we performed a single-center, long-term follow-up analysis of 38 patients who participated in the MT103-104 phase 1 trial. We found no evidence for long-term toxicities, especially no blinatumomab-induced neurocognitive impairments. For the entire study population, the median overall survival (OS) was 4.6 years. Remarkably, patients who had received ≥60 µg/m2 per day and responded to blinatumomab achieved a median OS of 7.7 years. Of note, 6 of the surviving patients treated at the MTD have been treatment-free for more than 7 years. In contrast, patients who were treated at dose levels below the MTD had a median OS of only 1.1 years. These results indicate that 60 µg/m2 per day seems to represent the targeted dose level of blinatumomab required for durable remission in R/R B-NHL. Here, we provide the first clinical evidence that blinatumomab lacks long-term toxicity and has the potential to induce sustained remissions in patients with R/R B-NHL.

2005-06-01·Carbohydrate Research4区 · 化学

The structure of the antigenic O-polysaccharide of the lipopolysaccharide of Edwardsiella ictaluri strain MT104

4区 · 化学

Article

作者: Ludmila Nossova ; William W. Kay ; Malcolm B. Perry ; Evgeny Vinogradov

The structural characterization of the antigenic O-polysaccharide component of the lipopolysaccharide produced by the fish pathogenic bacterium Edwardsiella ictaluri MT104 was undertaken by the application of NMR spectroscopy and chemical analysis. The O-chain was found to be a linear polymer of a repeating tetrasaccharide unit composed of D-glucose, 2-acetamido-2-deoxy-D-galactose, and D-galactose in a 1:2:1 ratio having the structure: [carbohydrate structure]; see text.

2005-03-01·International Journal of Systematic and Evolutionary Microbiology3区 · 生物学

Novosphingobium lentum sp. nov., a psychrotolerant bacterium from a polychlorophenol bioremediation process

3区 · 生物学

Article

作者: Kämpfer, Peter ; Tiirola, Marja A. ; Busse, Hans-Jürgen ; Männistö, Minna K.

A polychlorophenol-degrading strain, designated MT1T, and three MT1-like strains, MT101, MT103 and MT104, were isolated from a cold (4–8 °C) fluidized-bed process treating chlorophenol-contaminated groundwater in southern Finland. The organisms were Gram-negative, rod-shaped, catalase-positive, non-spore-forming and non-motile. Phylogenetic analysis based on 16S rRNA gene sequences indicated that the strains belonged to theα-4 subclass of theProteobacteriaand were members of the genusNovosphingobium. The highest 16S rRNA gene sequence similarity observed for these strains was 96·5 % with the type strains ofNovosphingobium hassiacum,Novosphingobium aromaticivoransandNovosphingobium subterraneum. Chemotaxonomic data (major ubiquinone: Q-10; major polyamine: spermidine; major polar lipids: phosphatidylethanolamine, phosphatidylglycerol, diphosphatidylglycerol, phosphatidylcholine and sphingoglycolipid; major fatty acids: 18 : 1ω7c, 16 : 1ω7cand 2-OH 14 : 0) as well as the ability to reduce nitrate supported the affiliation of the strains to the genusNovosphingobium. Based on the phylogenetic analysis, whole-cell fatty acid composition as well as biochemical and physiological characteristics, the MT1-like strains were highly similar and could be separated from all recognizedNovosphingobiumspecies. The novel speciesNovosphingobium lentumsp. nov. is proposed to accommodate strains MT1T(=DSM 13663T=CCUG 45847T), MT101 (=CCUG 45849), MT103 (=CCUG 45850) and MT104 (=CCUG 45851).

100 项与 MT104 相关的药物交易

登录后查看更多信息